

## Subject Index 2007

- adenocarcinoma: 4/161-5; 4/174-82  
 adenocarcinoma - radiography: 2/86-89  
 adult: 3/107-12  
 antibodies, monoclonal: 1/23-32; 3/115-122  
 antigens, CD 20: 1/23-32  
  
 bacterial toxins: 1/15-22  
 brachytherapy: 4/188-95  
 breast neoplasms - therapy: 3/115-122  
  
 cancer mortality: 4/183-7  
 cancer registry: 4/183-7  
 carcinoma, non - small - cell lung -  
   radiotherapy: 3/133-43  
 carcinoma, renal cell - epidemiology -  
   diagnosis - therapy: 2/64-71  
 cardiac tamponade: 4/161-5  
 catheter ablation: 1/33-8  
 colonic neoplasms-diagnosis, tomography,  
   X-ray computed: 1/1-12  
 comet assay: 1/15-22  
 computer - assisted: 3/133-43  
 cyanobacteria: 1/15-22  
  
 DNA damage: 1/15-22  
 dose - response relationship, radiation:  
   1/41-7  
 dose-response relationship, models,  
   statistical, TCP: 2/90-98  
  
 empyema, pleural: 2/57-62  
 ethics, medical: 2/80-85  
  
 IFN alfa: sup1/S43-S45  
 ileocecal valve: 3/107-12  
 intestinal obstruction: 2/86-89; 3/107-12  
 intraoperative period: 4/188-95  
 intussusception: 3/107-12  
 jejunal neoplasms: 2/86-89  
  
 lung neoplasms: 4/161-5  
 lung neoplasms - pathology, biopsy needle:  
   3/99-106  
  
 lung neoplasms - surgery: 1/33-8; 3/144-51  
 lymphatic metastasis - radionuclide  
   imaging: 4/167-73  
 lymphoma, B-cell - therapy: 1/23-32  
  
 magnetic resonance imaging: 1/1-12  
 mediastinitis: 2/57-62  
 microsatellite repeats: 3/123-32  
  
 neoplasms metastasis: 1/39-40  
 neoplasms, multiple primary: 2/80-85  
 nephrectomy: 2/64-71  
 NTCP, iso-effect, DVH: 1/41-7  
  
 oncogenes: 4/174-82  
 osteosarcoma - diagnosis - therapy:  
   3/152-60  
  
 pancreatic neoplasms: 1/39-40  
 pelvic neoplasms - radiotherapy: 1/48-55  
 periapical abscess - complications: 2/57-62  
 pericardial effusion: 4/161-5  
 periosteum: 3/152-60  
 pneumothorax: 3/99-106  
 Poisson distribution: 2/90-98  
 prognosis: 2/80-85  
  
 quality of life: 3/144-51  
  
 radiation effects: 3/123-32  
 radiation ionizing: 3/123-32  
 radiotherapy dosage: 2/90-98; 4/188-95;  
   4/196-202  
 radiotherapy dosage - methods: 1/48-55  
 radiotherapy planning: 3/133-43  
 radiotherapy, conformal: 3/133-43  
 rats, inbred F344: 1/15-22  
 receptor, ERB-2 - antagonists and  
   inhibitors: 3/115-122  
 rectal neoplasms - radiotherapy: 4/196-202  
 reverse transcriptase chain reaction:  
   4/174-82

## Supplement 1/2007

sample registration system: 4/183-7  
sentinel lymph node biopsy: 4/167-73  
stomach neoplasms - genetics: 4/174-82  
survival analysis: 2/64-71

testicular neoplasms - secondary: 1/39-40  
thoracotomy: 3/144-51  
vulvar neoplasms: 4/167-73  
vulvar neoplasms - radiotherapy - drug  
therapy - surgery - Bartholin gland:  
2/72-79

dakarbazin: S46-S52  
dejavniki tveganja: S1-S12  
dermoskopija: S18-S21  
diagnostika: S53-S55  
dopolnilno zdravljenje: S43-S45

elektrokemoterapija: S37-S42  
epidemiologija: S1-S12

incidenca: S1-S12  
indikacije: S22-S27; S28-S36; S37-S42;  
S43-S45

kirurgija: S22-S27

maligni melanom: S1-S12; S13-S17  
melanom: S18-S21; S22-S27; S28-S36; S37-  
S42; S43-S45; S46-S52; S53-S55

patologija: S13-S17  
preventiva: S18-S21

radioterapija: S28-S36

sistemsko zdravljenje: S46-S52  
stranski učinki: S22-S27; S28-S36; S43-S45

teledermoskopija: S18-S21

umrljivost: S1-S12

zdravljenje: S53-S55  
zgodnje odkrivanje: S18-S21